The Addition of Cixutumumab or Temozolomide to Intensive Multiagent Chemotherapy Is Feasible but Does Not Improve Outcome for Patients with Metastatic Rhabdomyosarcoma: A Report from the Children’s Oncology Group

Podobne knjige/članki

• Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
  od: Weigel, Brenda J., et al.
  Izdano: (2016)
• Metabolic response as assessed by (18)F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
  od: Harrison, Douglas J., et al.
  Izdano: (2020)
• Rhabdomyosarcoma: Review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee Experience and Rationale for Current COG Studies
  od: Malempati, Suman, et al.
  Izdano: (2012)
• Rhabdomyosarcoma in Infants Less than One Year of Age: A Report from the Children’s Oncology Group
  od: Malempati, Suman, et al.
  Izdano: (2011)
• Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group
  od: Hawkins, Douglas S., et al.
  Izdano: (2018)